期刊文献+

急性心肌梗死后心室重建与他汀干预△ 被引量:1

下载PDF
导出
摘要 急性心肌梗死(AMI)后心室重构是梗死区的心肌发生扩张和变薄,非梗死区心肌代偿性变化,心肌节段变长,使左室整体扩大。急性心肌梗死后左室重构是反映心肌梗死后预后的敏感指标,也是远期发生心脏性死亡最重要的危险因素之一,决定心肌梗死患者疾病与生命转归,因此心室重构的临床治疗已成为焦点与热点问题。
出处 《内蒙古中医药》 2012年第24期111-112,132,共3页 Inner Mongolia Journal of Traditional Chinese Medicine
基金 湖南省自然科学基金资助项目(10JJ6043) 湖南省重点建设学科资助
  • 相关文献

参考文献24

  • 1刘时武,丁世芳.他汀类药物的非调脂作用[J].华南国防医学杂志,2008,22(2):63-65. 被引量:13
  • 2刘英明,费宇行,杨晔.他汀类药物在慢性心力衰竭中的应用前景[J].心血管康复医学杂志,2008,17(1):86-89. 被引量:14
  • 3Hiroyuki Tsutsui. Mitochondrial Oxidative Stress and Heart Fail- ure. The Japanese Society of Internal Medicine. 2006.DOI:10.2169/ internalmedicine.45.1765.
  • 4A. William C. Stanley, Fabio A. Recchia, et al. Myocardial Sub- strate Metabolism in the Normal and Failing Heart. 2005. Physiol Rev 85:1093.
  • 5Daniel J. Lips, Leon J. deWindt, Dave J. W. van Kraaij, Pieter A. Doevendans,Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertro- phy. European Heart Journal. 2003; 24, 883.
  • 6Mittmann C,Eschenhagen T,Scholtz H.Cellular and molecular as- pects of contractile dysfunction in heart failure.Cardiovasc Res 1998,39:167-175.
  • 7Baig MK, mahon N,MckennaWJ,et al. The pathophysiology of ad- vanced heart failure.Am Heart,1998,135(6, part2):216-30.
  • 8Maan DL.Mechanisms and models in heart failure.Circulation, 1999,100(9) :999-1008.
  • 9Martin G. St. John Sutton, Norman Sharpe, Left Ventricular Re- modeling MterMyocardial Infarction Circulation. 2000;101:2981.
  • 10D. Struthers. Pathophysiology of Heart Failure Following My- ocardial Infarction.2005;91; 14.

二级参考文献84

  • 1魏广和,李清贤,张金国,丁乃喜,甘立军,张惠玲.辛伐他汀对高血压左室重构的影响[J].高血压杂志,2004,12(6):509-511. 被引量:9
  • 2刘歆,王燕,蔡尚郎.阿托伐他汀对充血性心力衰竭患者心功能和C-反应蛋白的影响[J].山东医药,2007,47(7):35-36. 被引量:5
  • 3[1]Ridker PM,Rifai N,Pfeffer MA,et al.Inflammation,pravastatin,and the risk of coronary events after myocardial infarction in patients with average cholesterol levels.Cholesterol and Recurrent Events (CARE) Investigators[J].Circulation,1998,98(9):839-844
  • 4[2]Marketou ME,Zacharis EA,Mkitovil D,et al.Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects[J].Angiology,2006,57(2):211-218
  • 5[3]Devaraj S,Chan E,Jialal I.Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome[J].J Clin Endocr Metab,2006,91(11):4489-4496
  • 6[4]Ridker PM,Rifai N,Pfeffer MA,et al.Long-term effect of pravastatin on plasma concentration of C-reactive protein[J].Circulation,1999,100(3):230-235
  • 7[5]Blake GJ,Ridker PM.Novel clinical markers of vascular wall inflammation[J].Circ Res,2001,89(9):763-771
  • 8[6]Seljeflot I,Tonstad S,Hjermann I,et al.Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease[J].Atherosclerosis,2002,162(1):179-185
  • 9[7]Romano M,Mezzetti A,Marulli C,et al.Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients:role of nitric oxide[J].J Invest Med,2000,48(3):183-189
  • 10[8]Albert MA,Danielson E,Rifai N,et al.Effect of statin therapy on C-reactive protein levels-The Pravastatin Inflammation/CRP Evaluation (PRINCE):a randomized trial and cohort study[J].JAMA,2001,286(1):64-70

共引文献45

同被引文献14

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部